TLSI:NSD-TriSalus Life Sciences Inc. (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 9.35

Change

0.00 (0.00)%

Market Cap

USD 0.26B

Volume

0.21M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-28 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

+3.74 (+2.97%)

USD 50.10B
ALGN Align Technology Inc

+2.24 (+0.81%)

USD 20.93B
SWAV Shockwave Medical Inc

-0.13 (-0.04%)

USD 12.41B
PODD Insulet Corporation

+8.29 (+4.81%)

USD 11.64B
BRKR Bruker Corporation

+1.84 (+2.43%)

USD 11.00B
MASI Masimo Corporation

+0.91 (+0.79%)

USD 7.20B
AXNX Axonics Modulation Technologie..

+0.24 (+0.36%)

USD 3.44B
LIVN LivaNova PLC

+1.77 (+2.88%)

USD 3.36B
PRCT Procept Biorobotics Corp

+3.88 (+5.94%)

USD 3.22B
IRTC iRhythm Technologies Inc

+1.18 (+1.19%)

USD 3.08B

ETFs Containing TLSI

TADS 4.26 % 0.00 %

N/A

N/A
CSF VictoryShares US Discover.. 0.33 % 0.35 %

+0.44 (+0%)

USD 0.05B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.65% 75% C 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.65% 75% C 78% C+
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.26B 62% D 52% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector